Clareo Health | PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers
PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lantheus Biosciences Ltd.
Age
45–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Healthy volunteers:
* males, \>/=50 and \</= 65 years of age
Cancer patients:
* males \>/= 45 years of age
* Patients had an MRI of the prostate and/or a positive choline or acetate PET/CT for diagnosis (Note: MRI, choline and acetate PET/CT are optional for primary prostate cancer patients) of recurrence prostate cancer and the primary cancer disease is/ will be histologically confirmed.
* The prostate cancer is histologically confirmed and results of histology are available.
* Patients with primary prostate cancer: \>/= 20 percent of biopsy material should be affected by cancer in the histopathological evaluation.
* Patients with primary prostate cancer: Patient is scheduled to undergo prostatectomy.
You may not be if
Concurrent severe and/or uncontrolled and/or unstable other medical disease (e.g. poorly controlled diabetes, congestive heart failure, myocardial infarction within 12 months prior to planned injection of BAY86-7548, unstable and uncontrolled hypertension, chronic renal or hepatic disease, severe pulmonary disease) which could compromise participation in the study
Known sensitivity to the study drug or components of the preparation.
